Meet the newest solution: COVID-19 and Influenza simultaneous detection in one sample

August 2021 – Mission, BC, Canada. Lumex Instruments has developed a rapid modern solution to distinguish COVID-19, Influenza A, and B from the same sample.* It is imperative to differentiate and identify the exact causative virus for appropriate therapeutic intervention, especially during the current COVID-19 pandemic.

The solution employs a pre-loaded microchip kit with the primers and probes lyophilized in the microchip for testing the Influenza A, B, and SARS-CoV-2. Upper respiratory tract samples (swabs) are used as samples. The estimated sample throughput is 84 samples per day on one instrument (per 8h work shift).

The main advantages of the Influenza and COVID-19 detection system on a microchip are low reagent consumption (1.2 μl per reaction), shipment under ambient conditions, the fast and convenient process of the PCR analysis. It demands fewer resources and fewer costs than current real-time PCR assays and instruments.

The analysis is run using microchip-based RT-PCR analyzer AriaDNA by Lumex Instruments. The instrument is compact and low-energy requiring, which allows using both in clinical and mobile laboratories settings.

Besides this innovation, Lumex Instruments offers the standard microchip RT-PCR COVID-19 detection system from swabs and saliva samples*, which provides accurate and reliable results just in 30 minutes.

* For research use only (RUO).